MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🔴 Moleculin Biotech is trading 6% down in after-hours trading with broader risk-off sentiment a possible factor
Moleculin Biotech is trading at $5.56, down 5.60% after hours versus the regular-session close, as broader risk-off sentiment may be weighing on shares. - No...
🔴 Moleculin Biotech is trading 6.3% down today as Nasdaq and S&P 500 fall
Moleculin Biotech is trading 6.3% lower at $5.91 on October 22, 2026, amid broad U.S. market weakness; risk-off sentiment is the most plausible available...
🔴 Moleculin Biotech is trading 6.1% down in pre-market with no clear catalyst established
Moleculin Biotech is trading 6.14% down at $5.81 pre-market; no clear catalyst is established. - The 1-for-20 reverse split took effect October 20, when...
🟢 Moleculin Biotech is trading 10% up today amid Part A enrollment completion in MIRACLE trial
Moleculin Biotech is trading at $5.85, up 10.38% at 9:43 a.m. ET on October 20, 2026, amid MIRACLE trial updates. - Part A enrollment is complete; full data...
Moleculin's Third Reverse Split in Three Years: Can a Shrinking Share Count Save a Company Running Out of Cash?
Shares of Moleculin Biotech sank another 9.1% to $0.26 on October 19, capping a brutal week that has erased more than 40% of the stock's value since October...
🔴 Moleculin Biotech is trading 21.18% down today after announcing a 1-for-20 reverse stock split
Moleculin Biotech is trading at $0.22, down 21.18%, after announcing a 1-for-20 reverse stock split effective October 20, 2026. - The company said the split...
🔴 Moleculin Biotech is trading 9.06% down today after announcing a 1-for-20 reverse split
Moleculin Biotech is trading 9.06% down at $0.26 after its October 16 announcement of a 1-for-20 reverse stock split. - The split takes effect October 20,...
Moleculin Shares Drop Over 16% After 1-for-20 Reverse Split Announcement
Moleculin Biotech announced a 1-for-20 reverse stock split of its common stock, effective at 12:01 a.m. ET on October 20, 2026. The stock is expected to begin...
🔴 Moleculin Biotech is trading 12.32% down with no clear catalyst identified
Moleculin Biotech is trading 12.32% down at $0.32, with no clear company-specific catalyst identified for October 16, 2026. - The latest listed company...
🔴 Moleculin Biotech is trading 18.27% down in pre-market — no clear company-specific catalyst identified
Moleculin Biotech is trading at $0.30, down 18.27% in pre-market, with no clear company-specific catalyst identified. - Its latest listed release is an...
🟢 Moleculin Biotech is trading 5.9% up in pre-market — no clear catalyst identified
Moleculin Biotech is trading at $0.39, up 5.94%, in pre-market, with no clear company-specific catalyst identified. - The company’s press-release page lists...
🟢 Moleculin Biotech is trading 5.4% up in after-hours trading with no clear company-specific catalyst
Moleculin Biotech is trading 5.38% up at $0.39 in after-hours, with no clear company-specific catalyst identified. - Its regular-session close was $0.37 on...
🔴 Moleculin Biotech is trading 5.8% down
Moleculin Biotech is trading 5.8% lower at $0.39, with the cause of the October 15 decline still uncertain. - Available search results showed no new...
🔴 Moleculin Biotech is trading 5.5% down alongside a 2.01% decline in biotech ETF XBI
Moleculin Biotech is trading at $0.41 (-5.51%), in line with biotech-sector weakness and broader equity declines. - Biotech ETF XBI was down 2.01% in the...
🟢 Moleculin Biotech is trading 14.8% up in pre-market ahead of October 14 Maxim Growth Summit presentation
Moleculin Biotech is trading at $0.50, up 14.75% in pre-market ahead of its scheduled presentation; available sources do not establish a causal link. - The...
🔴 Moleculin Biotech is trading 5% down today with no identified company-specific explanation
Moleculin Biotech is trading 5.07% lower at $0.42, with no company announcement identified that specifically explains the October 12 decline. - The company’s...
MBRX Shareholders Approve Potential Reverse Stock Split and Increased Equity Plan Shares
Moleculin Biotech, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved two key proposals: granting the Board of...
🟢 Moleculin Biotech rises 5.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Moleculin Biotech is trading 5.4% down with no confirmed company-specific catalyst
Moleculin Biotech is trading at $0.42 (-5.42%) amid biotech-sector weakness, though a direct cause is unconfirmed. - The latest company announcement found was...
🟢 Moleculin Biotech is trading 5% up in pre-market
Moleculin Biotech is trading at $0.47, up 5.25% in pre-market on October 7, 2026; available coverage identifies no company-specific catalyst. - Shares closed...